Second pivotal study of sustained-exposure otic dexamethasone [OTO 104] in patients with Meniere's disease

Trial Profile

Second pivotal study of sustained-exposure otic dexamethasone [OTO 104] in patients with Meniere's disease

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Meniere's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Otonomy
  • Most Recent Events

    • 09 Oct 2014 According to an Otonomy media release, OTO-104 has been granted Fast Track designation by the U.S. FDA.
    • 12 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top